En Es
Products
Covid-19
Companies
Pre-Owned
News
Events
About Us       Join now!
Categories

Browse Products by Category

Critical Care

Emergency Medicine

Intensive Care

Respiratory Care

Anesthesiology Systems

Home Care

Rehabilitation

Other

Hospital Infrastructure

IT Equipment

Transportation Systems

Waste Management

Other

Medical Imaging

Computed Tomography

Digital Radiography

Image Management Systems

Interventional Radiology

Magnetic Resonance Imaging

Mammography

PACS/RIS

Positron Emission Tomography

Radiation Safety

Radiography

Single-Photon Emission Computed Tomography

Ultrasound

Other

Patient Care

Bariatric Care

Beds

Examination Equipment

Other

Surgery

Endoscopy

Laparoscopy

Laser Surgery

Operating Room Equipment

Sterilization

Surgical Implants

Surgical Instruments

Waste Management

Other

Expo: Clinical Laboratory

Blood & Blood Gas Analyzers

Cell Counters

Centrifuges

Clinical Chemistry Analyzer

Coagulation Analyzers

General Lab

Hematology Analyzers

Immunoassay Systems

Lab Glassware

Microplate Reader

Microscopes

Pipettes

Rapid Tests

Ready-to-use Kits for Analysis

Urine Analyzer

Point-Of-Care Testing

Browse Products by Category

Close

Avacta Life Sciences Ltd.

Avacta Life Sciences Ltd.

Avacta Life Sciences Ltd. is a biotechnology company that develops safe and efficacious drugs, and high performing diagnostics based on its proprietary Affimer® and pre|CISION™ platforms. Avacta’s therapeutics division develops novel cancer immunotherapies and its diagnostics division develops high performing diagnostic ...
Products Covid-19Summary
Close

Covid-19 Avacta Life Sciences Ltd.

Clinical Laboratory

SARS-CoV-2 Antigen Lateral Flow Test
AffiDX SARS-CoV-2 Antigen Lateral Flow Test

The Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test is a qualitative in vitro diagnostic (IVD) test to detect SARS-CoV-2 antigen in human anterior nasal swabs. It is an ideal solution for point-of-care and decentralized testing to identify individuals with higher viral loads of SARS-CoV-2 that increase the likelihood of transmitting the infection to others. The test is wholly developed and manufactured in the UK utilizing accurate, flexible Affimer technology, and validated against emerging variants of SARS-CoV-2.
More details
Close

About Avacta Life Sciences Ltd.

Avacta Life Sciences Ltd. is a biotechnology company that develops safe and efficacious drugs, and high performing diagnostics based on its proprietary Affimer® and pre|CISION™ platforms. Avacta’s therapeutics division develops novel cancer immunotherapies and its diagnostics division develops high performing diagnostics as well as works with partners world-wide to develop Affimer reagents.

Recently updated

Reagents
Affimer Reagents in Affinity Purification

Affimer technology offers unique solutions in the field of affinity purification through the ability to develop highly specific and stable capture reagents for a wide-range of novel targets. The robust nature of Affimer reagents allows them to withstand industrial cleaning-in-place conditions without significant leaching, while highly reproducible manufacturing assures the consistency of supply. Affimer reagents can be engineered to orient the binder on the resin to optimize target binding. Implementing Affimer reagents in affinity chromatography and bioprocessing applications opens up the potential of unmet needs in this field.
More details

Immunoassay Reagents
Affimer Immunoassay Reagents

Affimer reagents have been successfully used to detect and quantify antigens across a broad range of immunoassay platforms. Highly specific Affimer binders can be generated to a wide variety of novel targets and routinely show minimal matrix effects within the assay environment. The application of these binders as capture reagents within an immunoassay can increase the potential specificity and dynamic range of the assay, delivering improved accuracy and the opportunity to multiplex sample analysis.
More details

SARS-CoV-2 Antigen Lateral Flow Test
AffiDX SARS-CoV-2 Antigen Lateral Flow Test

The Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test is a qualitative in vitro diagnostic (IVD) test to detect SARS-CoV-2 antigen in human anterior nasal swabs. It is an ideal solution for point-of-care and decentralized testing to identify individuals with higher viral loads of SARS-CoV-2 that increase the likelihood of transmitting the infection to others. The test is wholly developed and manufactured in the UK utilizing accurate, flexible Affimer technology, and validated against emerging variants of SARS-CoV-2.
More details

Clinical Laboratory

Reagents
Affimer Reagents in Affinity Purification

Affimer technology offers unique solutions in the field of affinity purification through the ability to develop highly specific and stable capture reagents for a wide-range of novel targets. The robust nature of Affimer reagents allows them to withstand industrial cleaning-in-place conditions without significant leaching, while highly reproducible manufacturing assures the consistency of supply. Affimer reagents can be engineered to orient the binder on the resin to optimize target binding. Implementing Affimer reagents in affinity chromatography and bioprocessing applications opens up the potential of unmet needs in this field.
More details

Immunoassay Reagents
Affimer Immunoassay Reagents

Affimer reagents have been successfully used to detect and quantify antigens across a broad range of immunoassay platforms. Highly specific Affimer binders can be generated to a wide variety of novel targets and routinely show minimal matrix effects within the assay environment. The application of these binders as capture reagents within an immunoassay can increase the potential specificity and dynamic range of the assay, delivering improved accuracy and the opportunity to multiplex sample analysis.
More details

SARS-CoV-2 Antigen Lateral Flow Test
AffiDX SARS-CoV-2 Antigen Lateral Flow Test

The Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test is a qualitative in vitro diagnostic (IVD) test to detect SARS-CoV-2 antigen in human anterior nasal swabs. It is an ideal solution for point-of-care and decentralized testing to identify individuals with higher viral loads of SARS-CoV-2 that increase the likelihood of transmitting the infection to others. The test is wholly developed and manufactured in the UK utilizing accurate, flexible Affimer technology, and validated against emerging variants of SARS-CoV-2.
More details
Copyright © 2000-2024 TradeMed.com. All rights reserved. | Terms And Conditions